Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Kimball

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
NPJ Breast Cancer|April 18, 2019
Therapeutic targeting of <i>BRCA1</i> and <i>TP53</i> mutant breast cancer through mutant p53 reactivationBing Na, Xin Yu, Tracy Withers, et al.
Journal of Medicinal Chemistry|February 4, 2021
Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53John A Gilleran, Xin Yu, Alan J Blayney, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinasesRaj N Misra, David B Rawlins, Hai-yun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2018
Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer TherapeuticsXin Yu, Samuel Kogan, Ying Chen, et al.
Molecular Cancer Therapeutics|June 15, 2019
Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper BindingSaif Zaman, Xin Yu, Anthony F Bencivenga, et al.
Molecular Pharmacology|February 25, 2015
Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophoreAdam R Blanden, Xin Yu, Aaron J Wolfe, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinasesRaj N Misra, Hai-yun Xiao, David K Williams, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2006
Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3Brian E Fink, Ashvinikumar V Gavai, John S Tokarski, et al.
Targeted Oncology|June 8, 2017
Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular CarcinomaMonica Bartucci, Mohamed S Hussein, Eric Huselid, et al.
Journal of Medicinal Chemistry|September 30, 2009
Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetesNicole C Goodwin, Ross Mabon, Bryce A Harrison, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
NPJ Breast Cancer|April 18, 2019
Therapeutic targeting of <i>BRCA1</i> and <i>TP53</i> mutant breast cancer through mutant p53 reactivationBing Na, Xin Yu, Tracy Withers, et al.
Journal of Medicinal Chemistry|February 4, 2021
Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53John A Gilleran, Xin Yu, Alan J Blayney, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2003
1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinasesRaj N Misra, David B Rawlins, Hai-yun Xiao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2018
Zinc Metallochaperones Reactivate Mutant p53 Using an ON/OFF Switch Mechanism: A New Paradigm in Cancer TherapeuticsXin Yu, Samuel Kogan, Ying Chen, et al.
Molecular Cancer Therapeutics|June 15, 2019
Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper BindingSaif Zaman, Xin Yu, Anthony F Bencivenga, et al.
Molecular Pharmacology|February 25, 2015
Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophoreAdam R Blanden, Xin Yu, Aaron J Wolfe, et al.
Bioorganic & Medicinal Chemistry Letters|May 6, 2004
Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinasesRaj N Misra, Hai-yun Xiao, David K Williams, et al.
Bioorganic & Medicinal Chemistry Letters|January 3, 2006
Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3Brian E Fink, Ashvinikumar V Gavai, John S Tokarski, et al.
Targeted Oncology|June 8, 2017
Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular CarcinomaMonica Bartucci, Mohamed S Hussein, Eric Huselid, et al.
Journal of Medicinal Chemistry|September 30, 2009
Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetesNicole C Goodwin, Ross Mabon, Bryce A Harrison, et al.
Pageof 5